Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
暂无分享,去创建一个
H. Moch | J. Kononen | L. Bubendorf | G. Sauter | R. Simon | P. Schraml | J. Torhorst | A. Schötzau | A. Nocito | C. Bucher | K. Wilber | M. Mihatsch | T. Hübscher | H. Moch | L. Bubendorf | Joachim Torhorst | Michael M. Mihatsch | Ronald Simon | Antonio Nocito | Tanja Hübscher | Christoph Bucher | Andreas Schötzau
[1] R. Simon,et al. Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.
[2] R. Ridolfi,et al. HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.
[3] M. Bui,et al. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. , 2000, Annals of clinical and laboratory science.
[4] N. Sneige,et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.
[5] D. Visscher,et al. Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.
[6] J. Klijanienko,et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER‐2/neu gene amplification in breast cancer fine‐needle samples , 1999, Cancer.
[7] H. Moch,et al. Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.
[10] D. Carter. TNM Classification of Malignant Tumors , 1998 .
[11] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[12] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[13] J. Brisson,et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[14] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[16] L. Holmberg,et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Waldman,et al. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. , 1996, Acta cytologica.
[20] L. Skoog,et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European Journal of Cancer.
[21] L. Norton,et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis , 1995, Cancer.
[22] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[23] B. Têtu,et al. Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.
[24] S. Ciatto,et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. , 1993, British Journal of Cancer.
[25] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[26] S Toikkanen,et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Noguchi,et al. C‐erbb‐2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node‐positive breast cancer , 1992, Cancer.
[29] P Boracchi,et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Ménard,et al. Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.
[31] W. Gullick,et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. , 1991, Cancer research.
[32] W. McGuire,et al. Follow-up study of HER-2/neu amplification in primary breast cancer. , 1991, Cancer research.
[33] W. McGuire,et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. , 1990, Cancer research.
[34] S. Hirohashi,et al. correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.
[35] S. Skates,et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. , 1989, Cancer research.
[36] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.